These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

92 related items for PubMed ID: 15866635

  • 1. High initial blood levels of tacrolimus in overweight renal transplant recipients.
    Rodrigo E, de Cos MA, Sánchez B, Ruiz JC, Piñera C, Fernández-Fresnedo G, Palomar R, Pérez-Ceballos MA, Cotorruelo JG, Zubimendi JA, de Francisco AL, Arias M.
    Transplant Proc; 2005 Apr; 37(3):1453-4. PubMed ID: 15866635
    [Abstract] [Full Text] [Related]

  • 2. Higher initial tacrolimus blood levels and concentration-dose ratios in kidney transplant recipients who develop diabetes mellitus.
    Rodrigo E, de Cos MA, Fernández-Fresnedo G, Sánchez B, Ruiz JC, Piñera C, Palomar R, Cotorruelo JG, Gómez-Alamillo C, de Castro SS, de Francisco AL, Arias M.
    Transplant Proc; 2005 Nov; 37(9):3819-20. PubMed ID: 16386549
    [Abstract] [Full Text] [Related]

  • 3. Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients.
    Kuypers DR, Vanrenterghem Y.
    Clin Ther; 2004 Nov; 26(11):1834-44. PubMed ID: 15639695
    [Abstract] [Full Text] [Related]

  • 4. Evolution of tacrolimus blood levels and concentration-dose ratios in patients who develop new onset diabetes mellitus after kidney transplantation.
    Rodrigo E, Piñera C, de Cos MA, Sánchez B, Ruiz JC, Fernández-Fresnedo G, Palomar R, González-Cotorruelo J, Gómez-Alamillo C, de Castro SS, de Francisco AL, Arias M.
    Transpl Int; 2005 Oct; 18(10):1152-7. PubMed ID: 16162102
    [Abstract] [Full Text] [Related]

  • 5. Ten years of treatment with tacrolimus is related to an excellent renal function, allowing monotherapy in a large proportion of cases: unicentric results of the tacrolimus versus cyclosporine A European Multicentric Study in kidney transplant patients.
    Morales JM, Andrés A, Dominguez-Gil B, Arriola M, Gutiérrez MJ, Hernández E, Ortuño T, Praga M.
    Transplant Proc; 2005 Nov; 37(9):3738-42. PubMed ID: 16386523
    [Abstract] [Full Text] [Related]

  • 6. Obesity in renal transplantation: analysis of 2691 patients.
    Cofán F, Vela E, Clèries M, Catalan Renal Registry.
    Transplant Proc; 2005 Nov; 37(9):3695-7. PubMed ID: 16386509
    [Abstract] [Full Text] [Related]

  • 7. Effect of long-term tacrolimus immunosuppression on renal function in liver transplant recipients.
    Corman SL, Coley KC, Schonder KS.
    Pharmacotherapy; 2006 Oct; 26(10):1433-7. PubMed ID: 16999653
    [Abstract] [Full Text] [Related]

  • 8. Relative risk of new-onset diabetes during the first year after renal transplantation in patients receiving tacrolimus or cyclosporine immunosuppression.
    Hoitsma AJ, Hilbrands LB.
    Clin Transplant; 2006 Oct; 20(5):659-64. PubMed ID: 16968494
    [Abstract] [Full Text] [Related]

  • 9. An objective measure to identify pediatric liver transplant recipients at risk for late allograft rejection related to non-adherence.
    Venkat VL, Nick TG, Wang Y, Bucuvalas JC.
    Pediatr Transplant; 2008 Feb; 12(1):67-72. PubMed ID: 18186891
    [Abstract] [Full Text] [Related]

  • 10. High body mass index and posttransplant weight gain are not risk factors for kidney graft and patient outcome.
    Marcén R, Fernández A, Pascual J, Teruel JL, Villafruela JJ, Rodriguez N, Martins J, Burgos FJ, Ortuño J.
    Transplant Proc; 2007 Sep; 39(7):2205-7. PubMed ID: 17889138
    [Abstract] [Full Text] [Related]

  • 11. Clinical outcomes of renal transplantation using liquid chromatographic monitoring of tacrolimus.
    Borrows R, Chusney G, Loucaidou M, James A, Stichbury J, Van Tromp J, Cairns T, Griffith M, Hakim N, McLean A, Palmer A, Papalois V, Taube D.
    Ther Drug Monit; 2006 Apr; 28(2):269-73. PubMed ID: 16628143
    [Abstract] [Full Text] [Related]

  • 12. Incidence and risk factors of clinical characteristics, tacrolimus pharmacokinetics, and related genomic polymorphisms for posttransplant diabetes mellitus in the early stage of renal transplant recipients.
    Numakura K, Satoh S, Tsuchiya N, Horikawa Y, Inoue T, Kakinuma H, Togashi H, Matsuura S, Tada H, Suzuki T, Habuchi T.
    Transplant Proc; 2005 May; 37(4):1865-7. PubMed ID: 15919487
    [Abstract] [Full Text] [Related]

  • 13. Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus.
    Chen JS, Li LS, Cheng DR, Ji SM, Sun QQ, Cheng Z, Wen JQ, Sha GZ, Liu ZH.
    Transplant Proc; 2009 Jun; 41(5):1557-61. PubMed ID: 19545678
    [Abstract] [Full Text] [Related]

  • 14. Paired kidney analysis of tacrolimus and cyclosporine microemulsion-based therapy in Chinese cadaveric renal transplant recipients.
    Cheung CY, Wong KM, Chan HW, Liu YL, Chan YH, Wong HS, Chak WL, Choi KS, Chau KF, Li CS.
    Transpl Int; 2006 Aug; 19(8):657-66. PubMed ID: 16827683
    [Abstract] [Full Text] [Related]

  • 15. The role of proinflammatory cytokine gene polymorphisms for development of insulin resistance after renal transplantation.
    Gençtoy G, Kahraman S, Arici M, Altun B, Erdem Y, Bakkaloğlu M, Yasavul U, Turgan C.
    Transplant Proc; 2006 Mar; 38(2):521-8. PubMed ID: 16549165
    [Abstract] [Full Text] [Related]

  • 16. Effect of obesity and overweight on cyclosporine blood levels and renal functions in renal adolescent recipients.
    Kasap B, Soylu A, Türkmen M, Kavukçu S, Bora S, Gülay H.
    Transplant Proc; 2006 Mar; 38(2):463-5. PubMed ID: 16549148
    [Abstract] [Full Text] [Related]

  • 17. Prevalence and risk factors of renal dysfunction after liver transplant: a single-center experience.
    Dehghani SM, Derakhshan A, Taghavi SA, Gholami S, Jalaeian H, Malek-Hosseini SA.
    Exp Clin Transplant; 2008 Mar; 6(1):25-9. PubMed ID: 18405241
    [Abstract] [Full Text] [Related]

  • 18. Effect of overweight on kidney transplantation outcome.
    Sancho A, Avila A, Gavela E, Beltrán S, Fernández-Nájera JE, Molina P, Crespo JF, Pallardó LM.
    Transplant Proc; 2007 Sep; 39(7):2202-4. PubMed ID: 17889137
    [Abstract] [Full Text] [Related]

  • 19. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G, Grazi GL, Sanjuan F, Wu Y, Mühlbacher F, Samuel D, Friman S, Jones R, Cantisani G, Villamil F, Cillo U, Clavien PA, Klintmalm G, Otto G, Pollard S, McCormick PA.
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [Abstract] [Full Text] [Related]

  • 20. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B.
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.